CTOs on the Move

United Home Health Services

www.uhhs.org

 
United Home Health Services has been serving the community for 22 years. Five dedicated women professionals, including three nurses, a social worker, and a psychiatrist, established UHHS in 1983. This group of professionals identified the need to make a
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million
  • www.uhhs.org
  • 2200 N Canton Center Rd Ste 250
    Canton, MI USA 48187
  • Phone: 734.981.8820

Executives

Name Title Contact Details

Similar Companies

DiagnosisONE Inc.

DiagnosisONE Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Santo Remedio

Santo Remedio is a Hispanic health and wellness startup that creates supplements and communities focused on preventative solutions to health problems, tailored to individual needs.

Shook Home

Shook Home is a Chambersburg, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Medically Home

We bring the hospital to you! We deliver advanced medical care to where and when patients and their families want and need it. The Medically Home Program gives you more care over a longer period of time. We know getting well from a hospital-level illness or surgical procedure takes weeks, not days. With the Medically Home Program, you get the time you need - at home - with a single care team available to you the entire time. One of the secrets to getting better is being involved in – and understanding – your own care. The more time you and your family spend with our clinical care team, the more tools you will have to be get better. We know it can be hard for you to deal with medication, nutrition, stress and other health issues. The relationship we build during our time together will help us support your goal of getting better. Having the time to get to know you and your family is a big part of how we deliver care, because you really matter.

Portola

Portola Pharmaceuticals is dedicated to developing and commercializing therapies that transform patient lives and advance patient care by changing treatment paradigms in thrombosis and other hematologic diseases. Our two lead assets are Bevyxxa® (betrixaban), and andexanet alfa. In addition, cerdulatinib is our investigational Syk/JAK inhibitor to treat hematologic cancers. These compounds come from our own internal research efforts and represent important advances to address significant unmet needs. We are employing novel strategies that may increase the likelihood of clinical, regulatory and commercial success of our potentially lifesaving therapies.